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Abstract: Elevated circulating levels of the adrenal androgen dehydroepiandrosterone (DHEA) and its sulfate 
(DHEAS) are associated with increased breast cancer risk in prospective studies. Genetic variants in hypothalamic-
pituitary-adrenal (HPA) axis genes may contribute to these circulating hormone levels, and consequently to breast 
cancer risk. No previous studies have examined the effects of genetic variants in HPA axis genes on breast cancer 
risk. We evaluated the associations of 49 single nucleotide polymorphisms (SNPs) in five HPA axis genes (NR3C1, 
NR3C2, CRH, CRHR1, and CRHBP) with the risk of breast cancer in the Women’s Insights and Shared Experiences 
(WISE) Study of Caucasians (346 cases and 442 controls), as well as African Americans (149 cases and 246 
controls). Of the 49 SNPs evaluated, one showed a nominal significant association (P for trend < 0.05) with breast 
cancer risk among Caucasians, and another two among African Americans. The age-adjusted additive odds ratio 
(OR) (95% confidence interval (95% CI)) of the SNP rs11747190[A] in the CRHBP gene for the risk of breast cancer 
among Caucasian women was 1.45 (1.09-1.94). The age-adjusted additive ORs (95% CIs) of two SNPs (CRHBP 
rs1700688[T] and CRHR1 rs17689471[C]) for the risk of breast cancer among African American women were 1.84 
(1.13-2.98) and 2.48 (1.20-5.13), respectively. However, these SNPs did not show significant associations after 
correction for multiple testing. Our findings do not provide strong supportive evidence for the contribution of genetic 
variants in these HPA axis genes to the risk of developing breast cancer in either Caucasians or African Americans. 
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Introduction
The hypothalamic-pituitary-adrenal (HPA) axis 
is a complex set of direct influences and feed-
back interactions among the hypothalamus, 
the pituitary gland, and the adrenal glands. HPA 
axis plays a fundamental role in regulating hor-
monal, metabolic and immunologic response to 
stressors. Previous epidemiologic and histo-
logical studies have provided compelling evi-
dence that the androgen, dehydroepiandros-
terone (DHEA) and its sulfate (DHEAS), that are 
almost exclusively produced by the adrenals 
[1], play a role in breast cancer etiology. In our 
prospective study [2, 3], postmenopausal 
women in the highest quartiles of DHEA and 
DHEAS were at a significant 3-4 fold excess risk 
of breast cancer. Results were unchanged when 
restricted to women whose bloods were col-
lected further in time from diagnosis, suggest-
ing that elevated adrenal androgens were not 
due to preclinical disease. Adrenal androgens 
have been associated with breast cancer in 
numerous prospective studies with risk esti-
mates for the highest vs. lowest categories 
ranging from approximately 2-4 [2-7]. In the 
pooled analysis of these studies, postmeno-
pausal women with the highest levels of DHEA 
were at a significant 2-fold excess risk of devel-
oping breast cancer [8]. Notably, the magnitude 
of the excess risk was comparable to that 
observed for estradiol. DHEA from plasma is 
found at high levels in cancerous human breast 
tissue [9]. Moreover, DHEA exhibits estradiol-
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like activity in aromatase transfected MCF-7 
breast cancer cells [10], indicating that DHEA 
could potentially stimulate breast tumor growth 
via conversion to estrogens. This is supported 
by our finding that the association of DHEAS 
with breast cancer is attenuated after adjusting 
for estradiol [11]. Overall, studies suggest that 
DHEA/S increases breast cancer risk in post-
menopausal women by acting as substrate for 
conversion to more active hormones like 
estradiol. 
Heritability of adrenal DHEAS levels is estimat-
ed to be 0.58 [12], suggesting that genetics 
contributes importantly to circulating levels, 
and by extension to breast cancer risk. However, 
none of the previous studies have evaluated 
associations of genetic variants in HPA axis 
genes with breast cancer risk. In this study, we 
examined the associations of 49 single nucleo-
tide polymorphisms (SNPs) in five HPA axis 
genes, including glucocorticoid receptor 
(NR3C1), mineralcorticoid receptor (NR3C2), 
corticotropin releasing hormone (CRH), cortico-
tropin releasing hormone receptor 1 (CRHR1) 
and corticotropin releasing hormone binding 
protein (CRHBP), with the risk of breast cancer 
in the Women’s Insights and Shared 
Experiences (WISE) study of Caucasians (346 
cases and 442 controls), as well as African 
Americans (149 cases and 246 controls).
Materials and methods
Study population and data collection
The WISE study is a population-based retro-
spective case-control study. Incident primary 
breast cancer cases were identified through 
hospitals and the Pennsylvania State Cancer 
Registry, and frequency-matched controls were 
identified from the community using random 
digit dialing. The source population for this 
study was from the three counties of 
Philadelphia (Pennsylvania), Delaware (Penn- 
sylvania), and Camden (New Jersey). Details of 
the study have been reported previously 
[13-15]. 
Potentially eligible cases were women residing 
in these counties at the time of diagnosis who 
were aged 50-79 years and newly diagnosed 
with breast cancer between July 1, 1999 and 
June 30, 2002. The cases were identified 
through active surveillance at hospitals in 
these counties. Pennsylvania Cancer Registry 
lists were reviewed quarterly to validate com-
pleteness of case ascertainment. Breast can-
cer diagnoses were validated by review of 
pathology reports and medical records. Breast 
cancer was confirmed if a pathology report was 
compatible with a first primary, invasive breast 
cancer. Controls were selected from the same 
geographic region as the cases and were fre-
quency matched to the cases on race, age (in 
5-year age groups) and calendar date of inter-
view (within 3 months). Eligible controls had no 
history of breast cancer. Both cases and con-
trols were required to live in a noninstitutional 
setting, to have a household telephone, to 
speak English, and to have no severe cognitive, 
language, or speech impairment. 
Telephone interviews were used to collect data 
on demographic characteristics, anthropome-
try, family history of breast cancer, menstrual 
and menopausal history, reproductive history, 
medical history, oral contraceptive (OC) and 
hormone replacement therapy (HRT) use, 
smoking and alcohol ingestion. Participants 
collected buccal swabs according to standard 
directions and mailed them to the University of 
Pennsylvania. A total of 346 cases and 442 
controls for Caucasians, as well as 149 cases 
and 246 controls for African Americans were 
included in this study.
Participants provided verbal informed consent 
for the interview and written informed consent 
for the buccal samples. The University of 
Pennsylvania Committee on Studies Involving 
Human Beings, the institutional review board at 
University of Maryland School of Medicine, and 
the institutional review boards of all the partici-
pating hospitals approved this study. 
Laboratory assays
We selected six putative functional single 
nucleotide polymorphisms (SNPs) for two HPA 
axis genes, NR3C1 (rs6190, rs6195, rs- 
10052957, and rs41423247) and NR3C2 (rs- 
5522 and rs2070951). Using the International 
HapMap project, we identified SNPs that effec-
tively cover the other three HPA axis genes of 
interest (CRH, CRHR1, and CRHBP). Some of 
these SNPs are in linkage disequilibrium; there-
fore, a more efficient set of tagging SNPs can 
be used to capture the same genetic variation 
[16]. Using Haploview program and a minimum 
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Table 1. Characteristics of breast cancer cases and controls in WISE case-control study
Caucasians African Americans
Characteristic Cases  (n = 346)
Controls 
(n = 442)
Cases  
(n = 149)
Controls  
(n = 246)
Age (yrs, mean) 63.4 62.5 62.2 61.0
Body-mass index (kg/m2, mean) 24.0 24.0 25.7 26.0
Age at menarche (yrs, mean) 12.5 12.7 12.8 12.7
Age at menopause (yrs, mean) 48.2 48.4 48.2 47.5
Age at first full term pregnancy among parous women (yrs, mean) 24.3 24.6 21.2 20.9
Number of full term pregnancies (%)   
    0 19.9 11.5 16.8 6.9
    1~2 32.7 39.6 43.0 41.5
    ≥ 3 47.4 48.9 40.3 51.6
Duration of breast feeding (%)    
    Never 69.1 56.1 66.9 67.1
    < 12 months 22.3 28.1 19.6 19.8
    ≥ 12 months 8.7 15.8 13.5 13.2
Menopausal status (%)    
    Premenopausal 7.2 7.7 7.4 8.1
    Postmenopausal 76.0 80.1 80.5 72.8
    Induced (e.g., surgical)/unknown 16.8 12.2 12.1 19.1
Family history of breast cancer in 1st degree relative (%)     
    Yes 18.8 19.0 18.1 11.4
    No 81.2 81.0 81.9 88.6
Duration of combined estrogen and progestin (CHRT) use (%)     
    Never/other HRT use 75.1 70.6 92.6 87.8
    < 3 years 8.4 13.6 1.3 6.9
    ≥ 3 years 16.5 15.8 6.0 5.3
Duration of oral contraceptive (OC) use (%)     
    Never 53.8 47.7 55.7 46.8
    < 3 years 22.0 26.6 19.5 22.4
    ≥ 3 years 24.3 25.7 24.8 30.9
r2 threshold of 0.8, we identified a set of 47 par-
simonious tagging SNPs with minor allele fre-
quency greater than 5% to capture genetic 
variation in each locus (introns and exons, as 
well as 20 kb upstream of the start of transcrip-
tion and 10 kb downstream of the end of tran-
scription) of three genes, including CRH (11 
SNPs), CRHR1 (21 SNPs), and CRHBP (15 
SNPs), in a race specific manner for Caucasians 
and African Americans separately. Information 
on these 47 SNPs and 6 putative functional 
SNPs in NR3C1 and NR3C2 genes is presented 
in Supplementary Table 1. 
We genotyped these SNPs using the Sequenom 
platform with 10 ng of all DNA samples in 384-
well format. Laboratory personnel were blinded 
to case-control status, and 3% blinded quality 
control samples were inserted to validate geno-
typing procedures; concordance for the blinded 
quality control samples was 100%.
Statistical methods
We used the x2 test to assess whether the gen-
otypes for all 53 SNPs were in Hardy-Weinberg 
equilibrium (HWE) among the controls. We eval-
uated the association between each SNP and 
breast cancer risk using unconditional logistic 
regression. An additive model was used to cal-
culate the P-value for trend on breast cancer 
risk according to an ordinal coding for genotype 
(0, 1 or 2 copies of SNP minor allele). All statisti-
cal analyses were two-sided and carried out 
using SAS V9.2 (SAS Institute, Cary, NC). 
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Table 2. SNPs significantly associated with breast cancer risk in WISE case-control study
SNP (gene) Caucasians African Americans
rs11747190 (CRHBP) Cases (%) Controls (%) Age-adjusted OR Multivariate-adjusted ORa Cases (%) Controls (%) Age-adjusted OR Multivariate- adjusted ORa
CC 245 (72.9) 344 (79.4) 1.00 1.00 108 (75.0) 155 (66.8) 1.00 1.00
CA 78 (23.2) 83 (19.2) 1.32 (0.93-1.87) 1.33 (0.93-1.90) 35 (24.3) 74 (31.9) 0.69 (0.43-1.10) 0.70 (0.42-1.16)
AA 13 (3.9) 6 (1.4) 3.10 (1.16-8.30) 3.23 (1.18-8.83) 1 (0.7) 3 (1.3) 0.50 (0.05-4.85) 0.44 (0.03-5.70)
Additive OR   1.45 (1.09-1.94) 1.47 (1.09-1.98)   0.69 (0.44-1.08) 0.69 (0.43-1.12)
P for trend   0.01 0.01   0.10 0.13
rs1700688 (CRHBP) Cases (%) Controls (%) Age-adjusted OR Multivariate-adjusted ORa Cases (%) Controls (%) Age-adjusted OR Multivariate- adjusted ORa
CC 336 (99.7) 418 (99.8) 1.00 1.00 103 (74.6) 199 (84.0) 1.00 1.00
CT 1 (0.3) 1 (0.2) 1.25 (0.08-20.2) 1.72 (0.10-28.3) 32 (23.2) 37 (15.6) 1.73 (1.01-2.94) 1.66 (0.94-2.92)
TT 0 (0.0) 0 (0.0) - 1.00 (0.98-1.02) 3 (2.2) 1 (0.4) 5.94 (0.60-58.4) 7.77 (0.73-83.1)
Additive OR   1.25 (0.08-20.2) 1.72 (0.10-28.3)   1.84 (1.13-2.98) 1.83 (1.10-3.05)
P for trend   0.87 0.71   0.01 0.02
rs17689471 (CRHR1) Cases (%) Controls (%) Age-adjusted OR Multivariate-adjusted ORa Cases (%) Controls (%) Age-adjusted OR Multivariate- adjusted ORa
TT 203 (61.5) 273 (63.5) 1.00 1.00 122 (86.5) 226 (94.2) 1.00 1.00
TC 106 (32.1) 126 (29.3) 1.13 (0.82-1.55) 1.15 (0.83-1.59) 19 (13.5) 14 (5.8) 2.48 (1.20-5.13) 2.72 (1.24-5.98)
CC 21 (6.4) 31 (7.2) 0.88 (0.49-1.58) 0.90 (0.49-1.65) 0 (0.0) 0 (0.0) - -
Additive OR   1.02 (0.81-1.29) 1.03 (0.81-1.31)   2.48 (1.20-5.13) 2.72 (1.24-5.98)
P for trend   0.88 0.79   0.01 0.01
aMultivariate-adjusted ORs are adjusted for age, age at menarche (< 12 yr, 12 yr, or > 12 yr), number of full term pregnancies (0, 1 to 2, or ≥ 3), menopausal status (premenopaus-
al, postmenopausal, or induced/unknown), family history of breast cancer in 1st degree relative (yes or no), body-mass index (< 25, 25 to 30, or ≥ 30), duration of CHRT use (never/
other HRT use, < 3 yrs, or ≥ 3 yrs), and duration of OC use (never, < 3 yrs, or ≥ 3 yrs).
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Results
Descriptive characteristics of cases and con-
trols in this study are summarized in Table 1. 
The mean age at diagnosis of breast cancer 
cases was 63.4 years for Caucasians and 62.2 
years for African Americans. Compared with 
controls, breast cancer cases in both 
Caucasians and African Americans had lower 
number of full term pregnancies. Among 
Caucasians, cases were less likely to breast-
feed, more likely to have used long-term (≥ 3 
years) combined estrogen and progestin hor-
mone replacement therapy (CHRT). Among 
African Americans, cases were more likely to 
have a family history of breast cancer in a first 
degree relative and less likely to have used 
long-term (≥ 3 years) oral contraceptives (OCs). 
The distributions of genotypes for four SNPs 
(rs6190, rs10052957, rs6999100, and rs- 
242936) among African Americans were not in 
Hardy-Weinberg equilibrium among controls (P 
for HWE = 0.000); thus were excluded from the 
analyses (Supplementary Table 1), and a total 
of 49 SNPs were included in the analyses. We 
evaluated the association of each SNP with 
breast cancer risk among Caucasians and 
African Americans separately. Of the 49 SNPs 
evaluated, one showed a nominal significant 
association with breast cancer risk among 
Caucasians (P for rs11747190, 0.01), and 
another two among African Americans (P for 
rs1700688, 0.01; P for rs17689471, 0.01). The 
age-adjusted additive odds ratio (OR) (95% con-
fidence interval (95% CI)) of the SNP 
rs11747190[A] in the CRHBP gene for the risk 
of breast cancer among Caucasian women was 
1.45 (1.09-1.94). The age-adjusted additive 
ORs (95% CIs) of two SNPs (CRHBP 
rs1700688[T] and CRHR1 rs17689471[C]) for 
the risk of breast cancer among African 
American women were 1.84 (1.13-2.98) and 
2.48 (1.20-5.13), respectively (Table 2). These 
findings remained consistent after adjusting for 
breast cancer-related factors (Table 2). After 
correction for multiple testing (Bonferroni cor-
rection), these SNPs did not show significant 
associations with breast cancer risk (all 
P-values > 0.05/49 = 0.001).
Considering that the relationship of genetic 
variants in HPA axis genes with breast cancer 
risk could be affected by menopausal status or 
HRT/OC use, for those three SNPs that showed 
nominal associations in the main effect analy-
ses, we conducted additional analyses in which 
premenopausal women or HRT/OC users were 
excluded. The results did not materially change 
for each of the three SNPs (data not shown). 
Discussion
Overall, our study did not show significant asso-
ciations between 49 SNPs in five HPA axis 
genes and breast cancer risk in both Caucasians 
and African Americans. None of the previous 
studies have examined the associations of 
genetic variants in HPA axis genes with breast 
cancer risk. 
Negative feedback by cortisol on the hypothala-
mus and pituitary acting via the glucocorticoid 
receptor (GR) is critical for containing the HPA 
response to stressors. The GR gene (i.e., 
NR3C1) is highly polymorphic [17] and includes 
4 common putative functional SNPs examined 
in this study. The A1220G SNP (rs6195) in 
NR3C1 is associated with higher BMI [18], high-
er waist-to-hip ratio (WHR) [19], enhanced corti-
sol suppression and increased insulin response 
to dexamethasone [20], and carriers have an 
increased cortisol response to a psychological 
stress test [21]. The NR3C1 Bcl1 restriction 
fragment length polymorphism (RFLP, rs- 
41423247) is associated with BMI, WHR, and 
enhanced cortisol response to a standard 
lunch [22], but a diminished cortisol response 
to a psychological stress test was reported for 
individuals homozygous for this polymorphism 
[21]. Also, carriers of the ER22/23EK polymor-
phism (rs6190) are less sensitive to negative 
feedback by cortisol [23], have lower fasting 
insulin levels [23], and lower c-reactive protein 
levels [24] compared to non-carriers. The TthIII 
I polymorphism (rs10052957) in the 5’ flanking 
region of NR3C1 has been reported to influ-
ence basal cortisol [25]. Under basal condi-
tions negative feedback of cortisol on the HPA 
axis is primarily via the mineralcorticoid recep-
tor (NR3C2) in the hypothalamus and anterior 
pituitary. A previous study reported that the 
I180V SNP (rs5522) in NR3C2 is associated 
with higher plasma cortisol following a stressor 
[26]. Also, a G-2C SNP (rs2070951) in the pro-
moter region of NR3C2 decreases transactiva-
tional activity in vitro [27]. 
Corticotropin releasing hormone (CRH) is 
secreted by the hypothalamus and stimulates 
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adrenocorticotropic hormone (ACTH) secretion 
by the pituitary. Individuals who are carriers of 
variant allele of CRH Xmn I polymorphism 
(rs5030875) and NR3C1 TthIII I polymorphism 
(rs10052957) have elevated cortisol levels 
before and during physiologic stress [28]. CRH 
stimulates pituitary ACTH secretion by binding 
to corticotrophin releasing hormone receptor 1 
(CRHR1). The CRHR1 gene is located on chro-
mosome 17 and is highly polymorphic. However, 
to our knowledge, none of the known polymor-
phisms in CRHR1 have been evaluated in rela-
tion to adrenal androgen or cortisol secretion or 
to adiposity. Corticotropin releasing hormone 
binding protein (CRHBP) inhibits activity of CRH 
by binding to it in the portal vascular system 
that connects the hypothalamus to the pitu-
itary. Several SNPs in CRHBP were related to 
alcohol abuse in Caucasians and to anxiety dis-
orders in Native Americans [29] but we are not 
aware of studies that evaluated associations 
with adrenal androgen or cortisol secretion or 
with obesity.
In summary, we evaluated the associations 
between 49 SNPs in five HPA axis genes and 
breast cancer risk in both Caucasians and 
African Americans. We did not find strong sup-
portive evidence for the contribution of genetic 
variants in these HPA axis genes to the risk of 
developing breast cancer, although three SNPs 
in two genes showed suggestive association. 
The sample size of this study was modest, and 
additional larger studies are warranted to con-
firm the suggestive associations observed in 
the present study. 
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Supplementary Table 1. 53 SNPs in five HPA axis genes
  Caucasians African Americans
Gene rs# Major/minor allele
MAF 
(%)a
P for 
HWE
Major/minor 
allele 
MAF 
(%)a
P for 
HWE
Glucocorticoid receptor (NR3C1) rs6190 G/A 2.7 0.569 G/A 0.0 0.000
 rs6195 A/G 2.9 0.537 A/G 0.8 0.897
 rs10052957 G/A 32.9 0.810 G/A 24.2 0.000
 rs41423247 G/C 34.8 0.333 G/C 20.7 0.008
Mineralcorticoid receptor (NR3C2) rs5522 A/G 11.4 0.503 A/G 8.7 0.059
 rs2070951 C/G 47.4 0.525 C/G 26.5 0.415
Corticotropin releasing hormone (CRH) rs3176921 T/C 9.1 0.753 C/T 42.05 0.759
rs5030875 T/G 3.5 0.492 T/G 16.09 0.001
 rs5030877 C/G 13.2 0.886 G/C 39.66 0.496
 rs6984398 T/C 5.7 0.152 T/C 41.85 0.012
 rs6990486 G/A 4.7 0.310 G/A 16.81 0.232
 rs6999100 T/C 12.5 0.117 T/C 48.39 0.000
 rs10090752 G/A 0.8 0.863 G/A 22.80 0.189
 rs10105164 C/T 3.7 0.576 C/T 32.92 0.176
 rs10957368 T/G 3.5 0.490 T/G 18.80 0.243
 rs11990370 G/T 9.0 0.806 G/T 50.00 0.795
 rs16932615 T/C 2.8 0.661 T/C 14.63 0.924
Corticotropin releasing hormone receptor 1 (CRHR1) rs110402 C/T 44.8 0.357 C/T 31.1 0.809
 rs171440 C/T 47.9 0.656 C/T 38.2 0.760
 rs171441 C/T 8.6 0.933 C/T 20.4 0.163
 rs173365 C/T 43.4 0.385 T/C 46.5 0.940
 rs242920 C/T 0.3 0.942 C/T 7.9 0.652
 rs242924 C/A 44.6 0.411 C/A 30.3 0.432
 rs242936 C/T 45.4 0.001 T/C 43.8 0.000
 rs242939 A/G 7.1 0.172 A/G 29.4 0.225
 rs242942 G/A 11.3 0.220 G/A 22.2 0.484
 rs242944 T/C 43.2 0.399 C/T 43.2 0.532
 rs4792825 A/G 9.6 0.250 A/G 13.9 0.012
 rs4792886 G/A 10.0 0.152 G/A 31.3 0.807
 rs6503448 A/G 41.9 0.352 A/G 23.1 0.604
 rs6503449 A/G 5.0 0.941 A/G 41.2 0.116
 rs12938031 A/G 37.8 0.282 A/G 10.3 0.686
 rs12944712 G/A 43.6 0.281 G/A 23.9 0.921
 rs12953076 C/T 15.7 0.363 C/T 16.1 0.358
 rs17689471 T/C 21.9 0.003 T/C 2.9 0.642
 rs17689966 A/G 42.3 0.074 G/A 49.1 0.944
 rs17763104 G/A 11.5 0.550 G/A 6.6 0.948
rs17763658 G/A 6.4 0.317 G/A 8.7 0.536
Corticotropin releasing hormone binding protein (CRHBP) rs1700680 C/T 36.2 0.996 C/T 37.3 0.079
 rs1700688 C/T 0.1 0.980 C/T 8.2 0.603
 rs1715747 A/G 31.2 0.205 G/A 37.7 0.081
 rs1715751 A/G 36.3 0.823 A/G 43.1 0.099
 rs1715752 G/A 36.2 0.856 G/A 37.1 0.068
 rs1715760 G/A 48.9 0.001 G/A 16.9 0.005
 rs2055628 G/T 10.0 0.884 G/T 12.9 0.252
 rs2135078 C/T 34.4 0.386 C/T 41.6 0.918
 rs7728378 T/C 39.4 0.125 C/T 24.9 0.044
 rs10062367 G/A 17.2 0.168 G/A 37.7 0.876
 rs10473984 G/T 3.9 0.397 G/T 29.2 0.168
 rs10474485 C/A 20.1 0.823 C/A 35.9 0.100
 rs10514082 T/C 12.9 0.980 T/C 9.0 0.958
 rs11747190 C/A 11.0 0.698 C/A 17.2 0.073
 rs28365143 G/A 5.2 0.867 G/A 16.3 0.007
aMinor allele frequency (MAF) was calculated among controls in this study.
